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PENCIRIAN FUNGSI INTERAKSI ANTARA FAKTOR TRANSKRIPSI CTCF 
TERPANGKAS DENGAN PROTEIN PENGIKAT KOTAK Y-1 DAN 
TERMINAL C DOMAIN POL II 
ABSTRAK 
CTCF adalah faktor transkripsi jejari 11-Zn, yang terlibat dalam pengawalan transkripsi, 
penebat, kawalan cetakan, dan pentakaktifan kromosom X. Dua daripada protein yang 
dapat berinteraksi dengan CTCF adalah YB-1 dan RNA Polymerase II. Protein yang 
pertama ialah faktor transkripsi YB-1 yang terdapat dalam kalangan Y-kotak, dan 
protein yang kedua ialah Subunit Besar RNA polimerase II ( LS Pol II) yang merupakan 
enzim utama untuk transkripsi. Berdasarkan kajian-kajian terdahulu, interaksi antara 
CTCF dan YB-1 berlaku pada ZF dan CSD domain manakala interaksi antara CTCF dan 
RNA Poll II berlaku pada C domain. Objektif kajian ini adalah untuk mengenalpasti 
interaksi anatara CTCF dan YB-1 di dalam titisan sel RGBM dan mengenalpasti motif 
pada CTCF C domain yang terlibat dalam interaksi dengan RNA Pol II. Hasil cerakin 
co-IP menunjukkan CTCF dapat membentuk kompleks dengan YB-1 dalam keseluruhan 
lisis sel RGBM. Interaksi antara kedua-dua protein tersebut turut digambarkan melalui 
cerakin in vitro pull-down. Berdasarkan hasil kajian, CTCF-ZF adalah satu-satunya 
xx 
 
domain yang berjaya diikat dengan YB-1 CSD, manakala domain yang selebihnya tidak 
menunjukkan sebarang interaksi. Selain itu, kajian ini juga berjaya menentukan interaksi 
antara CTCF dan LS RNA Pol II. Kajian terdahulu telah melaporkan interaksi antara 
kedua-dua protein tersebut berlaku di kawasan terminal C. Dua tapak dalam domain 
terminal C CTCF telah menunjukkan kepentingan dengan pengikatan Pol II CTD. 
Kajian ini turut menganalisis tujuh mutan varian CTCF C untuk mengenal pasti 
kesesuaian untuk diikat dengan Poll II CTD. Hasil co-IP menunjukkan interaksi positif 
antara semua mutan varian CTCF C dengan LS Poll II dalam titisan sel RGBM. 
Interaksi ini digambarkan menggunakan cerakin pull-down. Hasil cerakin pull-down 
menunjukkan motif EEEE merupakan kawasan penting bagi interaksi dengan Poll II 
CTD. Akhirnya, kesan CTCF C mutan varian pada kematian sel oleh apoptosis 
menunjukkan CTCF Complete Mutant (CM) memberi peratusan tertinggi dalam 
menyebabkan apoptosis dalam sel. Sebagai kesimpulan, CTCF ZF domain telah 
dikenalpasti sebagai domain yang dapat berinteraksi dengan YB-1 didalam sel RGBM. 
Selain itu, motif penting di dalam CTCF C domain telah Berjaya dikenalpasti di dalam 
kajian ini dimana EEEE motif merupakan motif yang penting bagi interaksi dengan 
RNA Pol II. Akhirnya, kajiian lanjutan diperlukan bagi menganalpasti implikasi motif in 
dalam interaksi antara CTCF and RNA Poll II.  
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FUNCTIONAL CHARACTERIZATION OF THE INTERACTIONS BETWEEN 
CTCF TRUNCATED TRANSCRIPTIONAL FACTOR WITH Y-BOX BINDING 
PROTEIN-1 AND THE CTD OF POL II 
ABSTRACT 
CCCTC sequence binding factor (CTCF) involved in the regulation of transcription, 
insulator function, control of imprinting and the X-chromosome inactivation. Two of the 
CTCF protein interacting partners were the transcriptional factor YB-1, a member of the 
Y-box binding protein 1 and the second protein was the large subunit of RNA 
polymerase II (LS Pol II) the principal enzyme for transcription. Previous studies have 
shown the interaction between CTCF and YB-1 occurred at the Zinc finger (ZF) and 
Cold Shock Domain (CSD) respectively whereas the interaction between CTCF and 
RNA Pol II occurred at the C-terminal domains (CTD) for both proteins. The objectives 
of this study are to determine the interaction between CTCF and YB-1 in Recurrent 
Glioblastoma Multiforme (RGBM) cell line and to identify the motif within CTCF CTD 
that is critical for binding with RNA Pol II CTD. CTCF truncated proteins were 
produced and used to map the interaction to YB-1 in RGBM cell line. The interaction of 
these truncated proteins was mapped using co-immunoprecipitation (Co-IP) and pull-
down assay and the functional significant of the interaction was characterized via 
mammalian two hybrid system. On the other hand, CTCF and RNA Poll II interactions 
xxii 
 
were characterized by identifying two sites within CTCF C-terminal domain important 
for the interaction and seven candidates CTCF C mutant variants named 1A, 1B, 1A1B, 
2A, 2B, 2A2B and CM deficient for binding with Poll II CTD were produced.            
The interaction of these mutants to Poll II CTD was characterized via Co-
immunoprecipitation (Co-IP) and pull-down assay, while the ability of these mutants to 
induce apoptosis in recurrent glioblastoma multiforme (RGBM) cell line was also 
analysed using Caspase 3/7 Glo assay. From the results obtained for CTCF and YB-1 
interactions, the co-immunoprecipitation (co-IP) showed that CTCF was able to form a 
complex with YB-1 in the RGBM total cell lysate. From pull down assay results, CTCF-
ZF was the only domain binds with YB-1 Cold Shock Domain (CSD) and the rest of 
domains fail to interact.  As for CTCF and RNA Pol II interactions, the Co-IP results 
shown positive interaction for CTCF wild-type and all the mutant variants in RGBM cell 
line. The interaction was further characterized using pull-down assay and EEEE motif 
was identified as a critical motif for binding to Pol II CTD. The effects of CTCF C 
mutant variants on cell death by apoptosis assay showed that CTCF complete mutant 
(CM) induced highest apoptosis percentage in the cell as compared to the wild-type 
CTCF. As conclusion, CTCF ZF domain was found to interact with YB-1 CSD in 
RGBM cell line and the important motif in CTCF C terminal region critical for Poll II 
CTD binding was successfully identified. The EEEE motif was found to be a critical 
motif for binding; hence further study is needed to determine the significant of these 
motifs in CTCF and RNA Poll II interactions. 
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CHAPTER 1 
INTRODUCTION 
1.1 GENERAL CHARACTERISTICS OF CTCF TRANSCRIPTION 
FACTOR  
CTCF is a multifunctional transcription factor that ubiquitously expressed in many 
species. It was categorized as a zinc finger transcriptional factor and it was reported to 
bind to the multiple target sites using different combinations of its 11 zinc finger 
domains (Filippova et al., 1996). It is known as 11 zinc fingers transcriptional factor 
and highly conserved from Drosophila melanogaster to humans (Ladomery and 
Dellaire, 2002).  
 
CTCF was originally identified as a protein that binds to the three repeats of the core 
sequence of CCCTC spaced ranging from 12-13 bp intervals within the chicken c-Myc 
promoter and was named as CCCTC Binding Factor, or CTCF. However, subsequent 
studies had shown CTCF was able to bind to various sequences in the human, mouse 
and avian c-Myc promoters suggesting its ability to have multiple roles in the 
biological functions (Lobanenkov et al., 1991).  
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CTCF was reported to be a multifunctional protein with the ability to bind to the 
genomic DNA sites ~40,000 within the mouse embryonic stem cell (Chen et al., 2008). 
It is functions include promoter activation or repression, hormone-responsive gene 
silencing, regulation of cell growth and apoptosis. In addition, CTCF was also reported 
to involve in the chromatin barrier, insulation and genomic imprinting (Ohlsson et al., 
2001). 
 
1.1.1 The CTCF gene 
CTCF is a single copy gene and human CTCF is localized at the chromosome region 
16q22.1 (Figure 1.1) which is often associated with genomic alterations in human 
tumours including breast and prostate (Filippova et al., 1998). The CTCF cDNA was 
first isolated, cloned and sequenced from chicken by Klenova et al. (1993) and the open 
reading frame (ORF) of CTCF gene is highly conserved between different species to 
which it was reported there was 93 % similarity between avian and human.  
 
1.1.2 The structure of the CTCF protein 
The CTCF protein is composed of three main domains which are N, Zinc Finger (ZF) 
and C (Figure 1.2) (Filippova et al., 1996). The ZF domain of CTCF was reported to 
contain ten fingers of C2H2 type and one finger of C2HC type (Fox et al., 1999). The 
third motif within the C-terminal region of CTCF contains two repeats of the PXXP-
signature characteristic of SH3-domain binding proteins. The protein was reported to 
consist of two isoforms which are CTCF-130 and CTCF-180. 
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Figure 1. 1 Human CTCF gene localized at the chromosome region 16q22.1 
(Klenova et al., 2002). The abbreviation of each gene is described as follow: 
 
GNAO1 : Guanine Nucleotide Binding Protein (G Protein) 
KIFC3  : Kinesin Family Member C3 
E2F4  : E2F Transcription Factor 4 
CTCF  : CCCTC-Binding Factor (Zinc Finger Protein) 
AGRP  : Agouti Related Neuropeptide  
NFATC3 : Nuclear Factor Of Activated T-Cells, Cytoplasmic, Calcineurin-  
                          Dependent 3               
CDH1  : Cadherin 1, Type 1 
PLCG2 : Phospholipase C, Gamma 2 (Phosphatidylinositol-Specific) 
CDH13 : Cadherin 13 
MC1R  : Melanocortin 1 Receptor (Alpha Melanocyte Stimulating Hormone     
                          Receptor) 
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Figure 1. 2 The structure of the CTCF protein. It consists of three main domains 
which are N, ZF and C (Filippova et al., 1996). It consists of PXXP motif 
which is a characteristic of SH3 binding domain.  
 
 
 
 
 
ZF domain 
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The first isoform, CTCF-130 cDNA was first cloned from the chicken genome with an 
open reading frame (ORF) of 727 amino acids corresponding to a polypeptide chain of 
82 kDa (Klenova et al., 1993). However in SDS-PAGE, this isoform migrates as a 130 
kDa protein (CTCF-130) and this could be due to the modifications of its N and the C-
terminal domains (Klenova et al., 1997). The second isoform of CTCF was discovered 
by the same group much later and it was reported to migrate in SDS-PAGE at 180 kDa. 
The increase in molecular weight could be due to some post-translational modification 
such as poly (ADP-ribosyl)ation (PARylation) that takes place in the cell.  
CTCF carries a unique feature to which it recognizes diverse DNA target sites through a 
combination of its 11 ZFs domain. This means each particular target sites utilizes 
combination of different ZFs for instance in chicken, CTCF utilized ZFs 2 to 7 to bind 
to the c-Myc promoter while in human, CTCF utilizes ZFs 4 to 11 to bind to c-Myc 
promoter (Ohlsson et al., 2001).  
1.2 POST-TRANSLATIONAL MODIFICATIONS OF CTCF 
The post-translational modification that takes place in the protein was reported to 
modulate their functions and affect their localization during the cell cycle. The post-
translational modification process was reported to take place in CTCF which includes 
phosphorylation, SUMOylation and Poly(ADP-ribosyl)ation or also known as 
PARylation.  
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These processes were found to be important in the regulation of CTCF functions to 
which specific phosphorylation by Casein kinase II (CK2) affects its function in the 
transcription regulation while Poly (ADP-ribosyl)ation modification affects its activity 
in the insulation function (MacPherson et al., 2009).  
 
1.2.1 Phosphorylation 
The involvement of CTCF phosphorylation in the regulation of differentiation was 
proposed earlier with the study conducted on the myeloid cell differentiation using four 
leukaemia cell lines: K562, HL60, U937 and THP1 (Delgado et al., 1999). The study 
suggested that phosphorylation of CTCF may be responsible for the regulation of gene-
specific lineage expression and may also be responsible for the activation of selected 
programmes in the biological functions (Delgado et al., 1999). A Study conducted by 
Klenova et al. (2001) showed that CTCF was able to be phosphorylated by protein kinase 
CK2 both in vivo and in vitro particularly in highly conserved sequences which were 
found in the C-terminal region. This group suggested that CTCF phosphorylation could 
be an important event in the cell for the modulation of CTCF function in regards to the 
activation of c-Myc promoter sequence.  
 
1.2.2 SUMOylation 
Sumoylation is a post-translational modification process, which involves an addition of 
SUMOs (small ubiquitin-like modifiers) to the protein of interest. This process can 
affect the protein’s structure and subcellular localization in the cell.  
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Previously reported study had shown that CTCF can be SUMOylated both in vivo and in 
vitro (MacPherson et al., 2009). Two sites within CTCF that were reported to be 
SUMOylated are the N and the C-terminal domains. This group has suggested that 
SUMOylation does not change the DNA binding properties of CTCF though it enhances 
the CTCF repressive functions on the c-Myc P2 promoter. In addition, another study 
conducted in 2010 revealed that SUMOylation of CTCF enhances the repression and 
enhancer blocking functions by reducing the transactivation and chromatin opening 
(Kitchen and Schoenherr, 2010). Furthermore, this process was reported to involve in 
the regulation of nuclear architecture, particularly the organisation of chromatin loops  
(MacPherson and Sadowski, 2010). Moreover, a recent study revealed that de-
SUMOylation of CTCF is linked to hypoxic stress although the mechanism of this 
process is still not well understood  (Wang et al., 2012).  
 
1.2.3 Poly (ADP-ribosyl)ation (PARylation) 
Poly (ADP) ribose polymerases (PARPs) is a type of protein mainly involved in the 
cellular processes involving DNA repair and programmed cell death (Beneke and 
Burkle, 2007). The earlier study had reported that CTCF was co-purified with PARP-1 
from the nuclear fractions of HeLa cell lysates (Yusufzai et al., 2004).                            
However,  the constitutive levels of this protein in the un-stimulated cells are usually 
low (D'Amours et al., 1999; Farrar et al., 2010) though in the presence of mitogenic 
stimuli or DNA damage the levels of poly-ADP-ribose may incline up to 500 times 
(Gagne et al., 2006).  Meanwhile, the researcher has conducted a study on the relation 
between PARylation with CTCF and reported that PARylation was essential for the 
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CTCF insulator function at the maternal ICR of the H19/Igf2 locus (Yu et al., 2004). 
Based on these findings, a model was proposed to which it was stated that PARylation 
of CTCF could be responsible in the formation of higher chromatin order structures at 
the maternal allele of the H19/Igf2 locus (Klenova and Ohlsson, 2005).  
 
1.3 THE BIOLOGICAL FUNCTIONS OF CTCF 
The capacity of CTCF protein binds to various DNA sequences, recruiting numerous 
protein partners thus suggesting its functional complexity in the biological system. 
Among the regulatory roles play by CTCF are promoter activation or repression, 
chromatin insulator protein, genomic imprinting and genomic organization (Klenova et 
al., 2001). The details of each regulatory roles played by CTCF are described in the 
following pages.  
 
1.3.1 CTCF as a transcriptional activator or repressor 
CTCF may act as a positive regulators of human amyloid β-protein precursor, APP gene 
(Vostrov and Quitschke, 1997). It regulates the over-expression of this protein which is 
known to be a contributing factor in the neurodegenerative disorders such as 
Alzheimer’s disease and Down’s syndrome (Mann et al., 1990). It was reported that the 
CTCF N-terminal domain was responsible for the activation of the APP gene promoter 
(Vostrov et al., 2002). Besides transcriptional activator, CTCF may also act as a 
transcriptional repressor. Previously reported study has shown that CTCF represses 
mouse, chicken and human c-Myc genes (Filippova et al., 1996; Lobanenkov et al., 
1990). The repression process carried out by CTCF was essential in the regulation of 
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cellular functions such as cell cycle progression, differentiation and apoptosis (Marcu et 
al., 1992; Packham and Cleveland, 1995).  
 
1.3.2 CTCF functions as a chromatin insulator protein 
The genome of higher eukaryotes consists of active and inactive genes separated by 
DNA sequences called chromatin insulators. The enhancer-blocking activities of CTCF 
were first described with the discovery of CTCF binding to 5'HS4 DNase I 
hypersensitive site (HS) of the insulator sequences upstream to the chicken β-globin 
locus (Bell et al., 1999). In humans, CTCF was shown to bind to two sites within the 5' 
and 3' flanking regions of the β-globin locus (Farrell et al., 2002). Studies of the spatial 
chromosomal organization in β-globin locus revealed that CTCF mediates cell type 
specific interactions in which β-globin domain folds into a globule with the LCR and the 
active globin genes on the periphery (Junier et al., 2012).  
 
1.3.3 CTCF and genomic imprinting 
The genetic information of eukaryotes is stored in two copies and in the mammalian 
systems, hundreds of genes exhibit parental imprinting. The gene expression in the 
biological system is in a selective manner to which and it can be attributed either from 
the mother or father. Genomic imprinting relies on the parental-specific methylation of 
DNA elements which control the differential expression of maternal or paternal alleles.  
Imprinted genes are often organized in the clusters such as insulin-like growth factor 2 
(Igf2/H19) genes. The Igf2/H19 genes were first identified as imprinted genes 
(Ferguson-Smith et al., 1991).  
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Both genes are located 80 kb apart in the genome and the monoallelic expression of 
Igf2/H19 locus is regulated by an imprinting control region (ICR) located 2 kb to 4.4 kb 
relative to the transcription start site of H19. It was proposed that the insulator factor is 
present at ICR in order to block the enhancer function at the maternal Igf2 gene.  
 
Studies have shown that CTCF involves in the differential methylation of Igf2/H19 
locus (Bell and Felsenfeld, 2000; Hark et al., 2000; Kanduri et al., 2000). The 
methylation process by CTCF occurred when the maternally inherited chromosome is 
unmethylated and CTCF binds to this site, resulting in the blocking of Igf2 gene 
activation by the enhancer. On the paternal chromosome, the ICR is methylated, thus 
preventing CTCF binding. As a result, the enhancer can bind to the Igf2 promoter and 
initiate its transcription of H19 gene. 
 
1.4 CTCF AS A CANDIDATE TUMOUR SUPPRESSOR 
The tumor suppressor genes encode proteins that suppress the tumor formation. Tumor 
suppressors have diverse functions and are involved in various cellular processes which 
include cell cycle control, detection and repair of DNA damage, protein degradation, 
mitogenic signalling, cell specifications, tumor angiogenesis and others (Sherr, 2004). 
Numerous studies have demonstrated that genetic and epigenetic changes of tumor 
suppressor genes could lead to functional abnormalities often causing cancer 
development (Gronbaek et al., 2007; Sadikovic et al., 2008).  
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CTCF is reported to be the candidate of tumor suppressor gene because of few factors 
such as the loss of CTCF heterozygosity locus in different malignancies, the association 
of specific ZF mutations in some cancers, the growth suppressive features of CTCF and 
the ability of CTCF to maintain epigenetic marks of growth- related genes via its 
insulator functions.  
The previous report on the cytogenetic studies at the 16q22.1 locus demonstrated that 
deletions at this locus are often associated with various cancers including breast 
(Driouch et al., 1997) and prostate (Latil et al., 1997). These two studies demonstrated 
the loss of heterozygosity (LOH) in the regions where tumor suppressor genes were 
located and defined the smallest region of overlap (SRO) for commonly deleted genetic 
material from the 16q chromosome. Additionally, the re-arrangement of the exons 
within the ZF domain associated with sporadic breast and prostate tumors were 
observed, further suggesting CTCF involvement as a tumor suppressor gene (Filippova 
et al., 1998). 
Analysis of the DNA sequences of the CTCF gene from different tumors identified 
missense mutations in breast, prostate and Wilms’ tumours. These mutations selectively 
affected the ability of CTCF to bind to the CTS in the genes (Filippova et al., 2002). 
Review that is more recent reported on CTCF harbouring 13 different mutations 
analyzed in 825 clinical patients with primary breast cancer (Cancer Genome Atlas, 
2012).  
12 
 
The previous study reported, the existence of acquired CTCF mutations in patients with 
transient abnormal myelopoiesis, mostly affecting infants with Down syndrome, that 
leads to acute megakaryoblastic leukaemia (AMKL) (Yoshida et al., 2013). However, 
some studies suggested that mutations in the CTCF gene do not always account for 
cancer development but rather abnormal CTCF function and epigenetic defects could 
possibly contribute more to tumor development (Recillas-Targa et al., 2011).  
CTCF binds to two CTSs upstream of the BRCA1 gene simultaneously with Sp1, which 
creates a protective barrier for DNA methylation leading to epigenetic silencing of these 
genes (Butcher et al., 2004). A similar mechanism of action is observed at the Rb gene 
promoter, where it protects the promoter against epigenetic silencing (De La Rosa-
Velazquez et al., 2007). The additional mechanism was also proposed by Phillips and 
Corces (Phillips and Corces, 2009) for the same gene loci where it was suggested that 
CTCF could interact with a transcriptional factor such as Kaiso to form alternative 
loops, thus protecting this locus via 3D organization. 
1.5 CTCF PROTEIN PARTNERS  
CTCF has been shown to interact with a number of proteins, via N, ZF and C-terminal 
domains that modulate CTCF-dependent molecular processes (Figure 1.3) (Ohlsson et 
al., 2010). One of the CTCF’s unique features to perform diverse functions could be 
attributed to the combinatorial usage of different ZFs to bind to DNA sequences and 
interacts with proteins.  
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Figure 1. 3 Structure of CTCF with its known interacting partners (Ohlsson et al., 
2010). 
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The previous reports have shown that, CTCF insulator function is regulated by a few 
protein partners such as transcription factor Kaiso (Defossez et al., 2005), chromatin 
helicase protein CHD8 (Ishihara et al., 2006), nucleophosmin/B23 (Yusufzai et al., 
2004), and cohesin (Wendt et al., 2008). CTCF was reported to form a complex with 
YY1 which this complex transactivate Tsix gene (Donohoe et al., 2007). In addition, 
CTCF interaction with the multifunctional Y-box DNA/RNA binding factor, YB1 
(Chernukhin et al., 2000), and the co-repressor of histone deacetylases, Sin3A (Lutz et 
al., 2000), resulted in the negative regulation of the c-Myc promoter. Other proteins 
reported to associate with CTCF include proliferating cell nuclear antigen, PCNA and 
breast cancer associated tumour suppressor protein BRCA-1 (Irminger-Finger et al., 
1999). 
It has been reported that CTCF can homodimerize via ZF and C-terminal domains. 
Homodimerization of CTCF is said to involve in the 3D organization of the genome via 
the interaction between distant DNA regions (Pant et al., 2004). Among nuclear 
architectural proteins CTCF interacts with are cohesin (Parelho et al., 2008), 
nucleophosmin/B23, topoisomerase II (Yusufzai et al., 2004) and components of 
nuclear lamina (Handoko et al., 2011).  
1.5.1 RNA Polymerase II 
In prokaryotes, one DNA-dependent RNA polymerase is sufficient to transcribe all 
genes into the variety of RNA molecules needed for the cell’s functioning (Egloff and 
Murphy, 2008).  
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However, that is not true for eukaryotes. Transcription of specific gene types is shared 
among three different RNA Polymerases. Polymerase I (Pol I) transcribes  genes 
encoding 18S, 28S, and 5.8S rRNA; whereas Polymerase III (Pol III) transcribes a range 
of short genes including those encoding tRNA and 5S RNA (Egloff and Murphy, 2008). 
Polymerase II (Pol II) is responsible for transcription of all protein-coding genes and 
also small nuclear RNAs. All three polymerases have the largest catalytic subunits 
which share homology between each other and with the largest subunit of bacterial 
polymerase (Smale and Kadonaga, 2003).  
 
1.5.1.1 CTCF interacts with RNA Pol II 
CTCF is a multifunctional protein with protein partners specific for each function it 
performs (Zlatanova and Caiafa, 2009). CTCF was reported to interact with the           
Large Subunit (LS) Pol II through the series of assays, in which the interaction was 
found in holo-Pol II complex and not in the TFIIH complex. The previous study had 
reported that, the interaction of CTCF occurred at the C-terminal domain of LS Pol II 
(Chernukhin et al., 2007).  
 
1.5.1.2 General characteristic features of RNA Pol II enzyme 
RNA polymerase II is a central enzyme in gene expression. It was classified into two 
forms which are “holo” polymerase and “core” polymerase (Figure 1.4). The “holo” 
enzyme of RNA Pol II consists of the “core” RNA Pol II and other complexes 
implicated in transcription, splicing, polyadenylation and DNA repair. 
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 These complexes include, but are not limited, to the general transcription factors 
(GTFs), the core Srb-mediator complex, the Srb10 cyclin-dependent kinase (CDK) 
complex, and the Swi-Snf complex (Myer and Young, 1998). The molecular weight of 
the “holo” enzyme is over 1MDa (Jenkins and Spencer, 2001).   
The “core” polymerase is a complex enzyme composed of multiple subunits (1-12 
subunits, from 6 to 600 kDa) with a molecular mass of 500 kDa (Myer and Young, 
1998). Genes which are encoding the subunits of the “core” enzyme are RPB1-RPB12. 
The two largest Pol II subunits, Rpb1 (220 kDa) and Rbp2 (150 kDa), are the most 
highly conserved and are homologous to the β and β’ subunits of the bacterial 
polymerase. Additionally, three yeast polymerases were reported to have several 
subunits in common which are Rpb5, Rpb6, Rpb8, Rpb10 and Rpb12 (Sugaya et al., 
2001).  
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Figure 1. 4 Structure of the RNA Polymerase II (holo and core enzymes) 
A schematic representation of the holo enzyme RNA Pol II (left) and the core enzyme 
(right). The core enzymes consists of 12 subunits (Rpb1-12), subunits 4 and 7 are not 
shown. The subunit 1 which represented in grey is the largest subunit of LS Pol II 
(Cramer et al., 2000).  
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1.5.1.3 The largest subunit of the RNA Pol II (LS Pol II) 
The largest subunit (LS Pol II) of the RNA Polymerase II, Rpb1, is the largest of all 
polypeptides associated with nuclear RNA polymerases. The ability of the LS Pol II to 
bind DNA and RNA is a unique feature of the LS Pol II, indispensable for its function 
(Wu and Chiang, 1998). The human LS Pol II consists of 1970 amino acids encoded by 
5913 nucleotides (Mita et al., 1995). It differs from other subunits in that it has a unique 
C-terminal domain. 
 
1.5.1.4 The structure and functions of the C-terminal domain (CTD) of the           
LS Pol II 
 
The C-terminal domain (CTD) of the Largest Subunit (LS Pol II) of the RNA 
Polymerase II is a unique domain of repetitive heptads (consensus sequence of 
Y1S2P3T4S5P6S7) that extends from the catalytic core of the enzyme (Chapman et al., 
2008). This domain is heavily modified by phosphorylation, glycosylation, and proline 
isomerization, reviewed in (Corden, 2013). In addition to modifying enzymes, a number 
of RNA processing factors and chromatin modification factors also interact with this 
domain. This region plays a role in positioning the catalytic core and allows for 
interaction with other sub-units of RNA Pol II, namely Rpb2 and Rpb6 (Cramer et al., 
2001). The CTD consists of three regions: starting from linker (closest to the catalytic 
core), the heptad repeats and “tip” (Figure 1.5) (Corden, 2013). The consensus heptads 
have been evolutionarily conserved except for the number of repeats, which differ 
among the species (Dahmus, 1996).     
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Figure 1. 5 Structure of the LS Pol II and the C-terminal domain (CTD)  
The above figure illustrates a schematic representation of the largest subunit (LS Pol II) 
of the RNA Pol II and the C-terminal domain with repetitive heptads                   
(Dahmus, 1996). 
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The CTD of the LS Pol II in mammalian cells has 52 repeats whereas  yeast has 26-27 
copies and  other eukaryotes contain intermediate number of repeats (Dahmus, 1996). 
There is a clear relationship between the length of the CTD repeats and genomic 
complexity of an organism. There was a study suggested that CTD is largely 
unstructured however, phosphorylation can influence the propensity of the CTD 
peptides to form β-turns and polyproline helices (Buratowski, 2003). 
The previous study reported that, multiple forms of the LS Pol II were identified by ion 
exchange chromatography, resulting in different forms termed as Pol IIo, IIa, and IIb 
which migrated differently in the SDS-PAGE. The most rapidly migrating IIb form was 
a proteolytic breakdown product lacking the CTD, whereas both forms IIo and IIa had 
the CTD but differed in their phosphorylation, in which IIo being highly 
phosphorylated. It was reported that, IIo form could be converted to the IIa form by a 
phosphatase treatment. The LS Pol II undergoes a reversible phosphorylation with the 
hypophosphorylated IIa form functioning in initiation and the hyperphosphorylated IIo 
form in elongation processes (Dahmus, 1995).  
Previous studies with deletions of the CTD repeats showed that deletion of the 31 
repeats interferes with viability in the cell (Meininghaus et al., 2000). The nonconsensus 
52
nd
 CTD repeat has an unusual 10 amino acids extension and shows a CKII 
phosphorylation (Chapman et al., 2004), and is also a binding site for Abl1 tyrosine 
kinase (Baskaran et al., 1999).  
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Deletion of the repeats 1 to 3 (Chapman et al., 2005) and the repeat 52 resulted in the 
LS Pol II degradation yielding the LS Pol IIb form. The LS Pol II without 52
nd
 repeat 
has the reduced ability to transcribe (Chapman et al., 2004) splice and 3'-end process 
pre-mRNA (Fong et al., 2003).  
1.5.2 Y-Box Protein Binding 1 (YB-1)  
The study on YB-1 and CTCF interaction was initiated after the discovery that CTCF 
and YB-1 exist in a complex in vivo (Chernukhin et al., 2000). YB-1 is a member of the 
family of Y-Box (an inverted CCAAT-box) binding factors (Matsumoto and Wolffe, 
1998). It is a multifunctional factor which is expressed in a wide range of cells. It 
participates in the regulation of diverse cell functions such as transcription, replication 
cell proliferation DNA repair, DNA unwinding (Ladomery and Sommerville, 1995) . 
YB-1 is also shown to be linked to cancer in which it controls the MDR1 gene which is 
involved in multi-drug resistance development in cancer cells (Matsumoto and Bay, 
2005).  
YB-1 was found to interact with other transcription factors, thus the direct interaction of 
YB-1 with the p65 (relA) protein activates the transcription of the human polyomavirus 
JC promoter (Raj et al., 1996). The synergistic interaction between YB-1 and Ap2 
transcription factor mediates high level of expression of the matrix-metalloproteinase-
gelatinase A gene (Mertens et al., 1998).  
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YB-1 was also found to form a functional heteromer with Purand the HIV-1 
transcription factor Tat (Ansari et al., 1999).  Interaction of YB-1 with YY-1 is required 
for regulation of the grp78 gene controlling pathways involved in the stress protection 
(Brehm et al., 1997).   
1.5.2.1 Y-Box protein family 
The Y-box protein is a family of DNA binding proteins that contain a highly conserved 
70 amino acid DNA domain, the so-called “cold shock domain”. The “cold shock 
domain” (CSD) region was identified as one of the most evolutionary conserved nucleic 
acid binding domains between bacteria, plants and animals. The name "Y box proteins" 
comes from the ability of the CSD to bind to the Y-box sequence [5’– CTGATTGG – 
3’] of DNA, which is an inverted CCAAT box, in the promoter region of many genes. 
Among vertebrates, several Y Box protein genes have been cloned and characterized 
which includes include rat (Hasegawa et al., 1991), chicken (Grant and Deeley, 1993). 
The human YB-1 was originally cloned from human B cell expression library for a 
protein that binds to the Y-Box in the promoter region of MHC class II gene. Then, two 
homologues of this gene dbpA and dbpB was further isolated from human placental 
cDNA expression libraries using the c-erb2 gene promoter as the probe. Sequence 
analysis revealed that dbpB was identical to the YB-1.  
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Previously reported study has isolated two clones identical to dbpA and dbpB (YB-1) 
cDNA after screening a -phage expression library with a DNA probe containing the 
human leukosialin CD43 promoter sequence which were found to have expression 
pattern, which are not restricted to only hematopoietic cells (Kudo et al., 1995). The 
dbpA was located on the chromosome 12p13 and dbpB on chromosome 1p34.  
 
 The dbpA was expressed in skeletal and heart muscles and the dbpB (YB-1) is found in 
skeletal muscle, kidney, lung and liver cells. The YB-1 protein is mainly located in the 
cytoplasm of the cell (Koike et al., 1997). Interestingly it was detected in both the 
cytoplasm and nucleus in various types of human cancers (Ohga et al., 1996).  
 
1.5.2.2 dbpA : organization, structure and function 
All Y-Box proteins contain three domains: the N terminal domain, cold shock domain 
(CSD) and C terminal domain (Figure 1.6). The dbpA gene consists of 10 exons 
spanning 24 kb of the genomic DNA. Its N terminal domain is encoded by the first exon, 
the cold shock domain (CSD) is encoded by the 2
nd
 to the 5
th
 exon and the C terminal 
domain by the 5
th
 to 8
th
 exons. However, the exon sequences of the N terminal domain 
of dbpA are found to have only 15 % homology with the dbpB's (YB-1) N-terminal 
domain, whereas its C terminal has 30 % homology compared to CSD, which shows 
96% sequence homology with its YB-1 counterpart.  
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Figure 1. 6 Domain structure of human dbpB (YB-1) and dbpA  
These genes consist of 3 main domains which are N, CSD and C-terminal domain. The 
light and dark shading represent non-coding sequences and the cold shock domains 
(CSD), respectively (Toh et al., 1998). 
 
 
 
 
 
